Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.
- These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.
- “This study demonstrated that rademikibart has a best-in-class potential, and if approved as a Q4W treatment, we believe could offer patients with AD a highly efficacious treatment with less frequent dosing than current approved treatments.
- I’d like to thank the patients, their families, the clinical and manufacturing teams, and all of our vendors that were an integral part of this trial.
- Patients that did not achieve EASI-50 (non-responders) were assigned to an open label Q2W rademikibart arm (n=86).